Drug Firm Claims Poor Legal Work|Cost It $216 Million In Antitrust Problems

LOS ANGELES (CN) - Mylan Pharmaceuticals claims poor legal work on antitrust issues by attorneys with Ervin, Cohen & Jessupcost it $216 million. The issues involved deal with generic drug supplier Profarmaco that raised the prices of lorazepam and clorazepate by 1,900 to 3,200 percent, leading to an FTC investigation. Mylan is represented in Superior Court by Parker Mills Morin.

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Email *

Submit